TRIGGER
Start date:Historic End date:
March 2014 Co-ordinated by:
National Health Services Blood and Transplant Services
Transfusion in Gastrointestinal Bleeding
Aim
To evaluate the feasibility and safety of implementing a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.
Trial Design
A multi-centre, feasibility, cluster randomised controlled trial comparing restrictive versus liberal blood transfusion strategies in adult patients admitted with acute upper gastrointestinal bleeding
Chief Investigator
Professor Mike Murphy & Dr, Vipul Jairath
Local PI
Professor Alasdair Gray
List of Publications – References
Vipul Jairath, Brennan C Kahan, Alasdair Gray, Caroline J Doré, Ana Mora, Martin W James, Adrian J Stanley, Simon M Everett, Adam A Bailey, Helen Dallal, John Greenaway, Ivan Le Jeune, Melanie Darwent, Nicholas Church, Ian Reckless, Renate Hodge, Claire Dyer, Sarah Meredith, Charlotte Llewelyn, Kelvin R Palmer, Richard F Logan, Simon P Travis, Timothy S Walsh, Michael F Murphy: Restrictive versus liberal blood transfusion for acute uppergastrointestinal bleeding (TRIGGER): a pragmatic, open-label,cluster randomised feasibility trial. The Lancet Published online May 6, 2015
Local PI
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Research Team
Judy Coyle
Scottish Research Nurse of the Year 2015 (SRNCN)
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.